α-amino-isobutyric acid isobutyl ester

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: α-amino-isobutyric acid isobutyl ester
• 英文别名: α-Amino-isobuttersaeure-isobutylester；2-Methylpropyl 2-amino-2-methylpropanoate
• 化学式: C₈H₁₇NO₂
• 分子量: 159.228
• InChiKey: AXJLXWAXGGFZSK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  α-amino-isobutyric acid isobutyl ester 生成 3,3,6,6-tetramethyl-2,5-dioxopiperazine
  参考文献：
  名称：

  Jacobson, Journal of the American Chemical Society, 1946, vol. 68, p. 2630

  摘要：

  DOI：
• 作为产物：
  描述：

  2-甲基丙氨酸 、 异丁醇 、 乙酰氯 生成 α-amino-isobutyric acid isobutyl ester
  参考文献：
  名称：

  MACKENZIE S. L., J. ASSOC. OFFIC. ANAL. CHEM., 70,(1987) N 1, 151-160

  摘要：

  DOI：

文献信息

• SOLUBLE GUANYLATE CYCLASE STIMULATORS
  申请人：Berger Raphaelle

  公开号：US20170174693A1

  公开（公告）日：2017-06-22

  The invention provides compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, Z, R 1 , R 2 , R 4 , R a , and the subscripts m, p, and q are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate (“cGMP”), and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose.

  该发明提供了Formula (I)的化合物或其药用盐，其中X、Y、Z、R1、R2、R4、Ra以及下标m、p和q如本文所述。这些化合物或其药用盐可以调节人体对环鸟苷酸单磷酸（“cGMP”）的产生，并通常适用于治疗和预防与扰乱的cGMP平衡相关的疾病。该发明还提供了包含Formula (I)的化合物或其药用盐的药物组合物。该发明还涉及使用这些化合物或其药用盐在治疗和预防上述疾病以及为此目的制备药物的方法。
• [EN] ANTIVIRAL OXIME PHOSPHORAMIDE COMPOUNDS<br/>[FR] COMPOSÉS OXIMES PHOSPHORAMIDES ANTIVIRAUX
  申请人：MERCK SHARP & DOHME

  公开号：WO2017106069A1

  公开（公告）日：2017-06-22

  Compounds of Formula I: I and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.

  式I的化合物及其药用盐可用于抑制HIV逆转录酶。这些化合物也可能对预防或治疗HIV感染以及预防、延缓或治疗艾滋病有用。这些化合物及其盐可作为药物组成部分，可选择与其他抗病毒药物、免疫调节剂、抗生素或疫苗组合使用。
• Soluble guanylate cyclase stimulators
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US10030027B2

  公开（公告）日：2018-07-24

  The invention provides compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, Z, R1, R2, R4, Ra, and the subscripts m, p, and q are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate (“cGMP”), and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose.

  本发明提供了式（I）化合物 或其药学上可接受的盐，其中 X、Y、Z、R1、R2、R4、Ra 和下标 m、p 和 q 如本文所述。这些化合物或其药学上可接受的盐类可以调节人体产生的环磷酸鸟苷（"cGMP"），通常适用于治疗和预防与 cGMP 平衡紊乱有关的疾病。本发明还提供了包含式（I）化合物或其药学上可接受的盐的药物组合物。本发明还涉及将这些化合物或其药学上可接受的盐用于治疗和预防上述疾病的方法，以及为此目的制备药物的方法。
• Aza-pyridone compounds and uses thereof
  申请人：Alios BioPharma, Inc.

  公开号：US10208045B2

  公开（公告）日：2019-02-19

  Disclosed herein are aza-pyridone compounds, pharmaceutical compositions that include one or more aza-pyridone compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an orthomyxovirus infection, with an aza-pyridone compound. Examples of an orthomyxovirus viral infection include an influenza infection.

  本文公开了偶氮吡啶酮化合物、包括一种或多种偶氮吡啶酮化合物的药物组合物，以及合成这些化合物的方法。本文还公开了使用氮杂吡啶酮化合物改善和/或治疗疾病和/或病症（包括正粘病毒感染）的方法。正粘病毒感染的例子包括流感病毒感染。
• Antiviral prodrugs of tenofovir
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10449208B2

  公开（公告）日：2019-10-22

  Compounds of Formula I: and pharmaceutically acceptable salts and co-crystals thereof are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.

  式 I 的化合物及其药学上可接受的盐类和共晶体可用于抑制 HIV 逆转录酶。这些化合物还可用于预防或治疗艾滋病病毒感染，以及预防、延缓艾滋病的发生或发展以及治疗艾滋病。这些化合物及其盐类可用作药物组合物的成分，也可与其他抗病毒剂、免疫调节剂、抗生素或疫苗结合使用。